Tag:
Fraunhofer Center for Molecular Biotechnology
Latest Headlines
Latest Headlines
Fiocruz granted royalty-bearing license from iBio
IBio, which focuses on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases, has granted a commercial, royalty-bearing
Medicago, BU design tobacco vax factories
Efforts to speed up vaccine manufacturing have shifted into overdrive now that flu season is here. Tobacco and virus-like particles are currently in the headlines for efforts geared at developing
DARPA efforts tweak tobacco-based vax making
The Defense Advanced Research Projects Agency is funding four efforts to develop vaccine manufacturing processes based on fast-growing tobacco plants. Under its Blue Angel initiative, begun in May
Plant-based H1N1 vax starts clinical trial
The Fraunhofer Center for Molecular Biotechnology and iBio have found a new possibility for H1N1 vaccines. Rather than using traditional vaccine ingredients, the Newark, NJ-based center uses
FDA OKs studies with iBio/Fraunhofer plant-based vax
Plant-based product developer iBio, which announced just before Labor Day a deal with GE Healthcare and the Fraunhofer Center for Molecular Biotechnology to develop biopharma and vaccine
